Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.

[1]  S. Wolf,et al.  Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age‐related macular degeneration , 2011, Acta ophthalmologica.

[2]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[3]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[4]  R. Guymer,et al.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.

[5]  P. Abraham,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. , 2010, American journal of ophthalmology.

[6]  S. Sivaprasad,et al.  Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration , 2010, British Journal of Ophthalmology.

[7]  L. Spielberg,et al.  Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  C. Costagliola,et al.  Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration , 2009, British Journal of Ophthalmology.

[9]  T. Ianchulev,et al.  A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. , 2009, Ophthalmology.

[10]  M. Potter,et al.  A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study , 2009, British Journal of Ophthalmology.

[11]  T. Busch.  APPROACHES TOWARD COMBINING PHOTODYNAMIC THERAPY WITH PHARMACEUTICALS THAT ALTER VASCULAR MICROENVIRONMENT , 2009, Retina.

[12]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[13]  U. Schmidt-Erfurth,et al.  Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration , 2008, British Journal of Ophthalmology.

[14]  F. Parmeggiani,et al.  Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[15]  A. Antoszyk,et al.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. , 2008, American journal of ophthalmology.

[16]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[17]  F. Parmeggiani,et al.  Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration , 2007, Pharmacogenetics and genomics.

[18]  Valerie Quarmby,et al.  Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. , 2007, Experimental eye research.

[19]  R. Bhisitkul,et al.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[20]  P. Kaiser.  Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration , 2007, Current medical research and opinion.

[21]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[22]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[23]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[24]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[25]  T. Ianchulev,et al.  Role of vascular endothelial growth factor in ocular angiogenesis. , 2006, Ophthalmology clinics of North America.

[26]  P. Kaiser,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[27]  U. Schmidt-Erfurth,et al.  Time course and morphology of vascular effects associated with photodynamic therapy. , 2005, Ophthalmology.

[28]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. , 2005, Archives of ophthalmology.

[29]  D. Antonetti,et al.  Regulation of tight junctions and loss of barrier function in pathophysiology. , 2004, The international journal of biochemistry & cell biology.

[30]  U. Schmidt-Erfurth,et al.  Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. , 2003, Investigative ophthalmology & visual science.

[31]  Michael Stur,et al.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.

[32]  B W Henderson,et al.  Role of cytokines in photodynamic therapy-induced local and systemic inflammation , 2003, British Journal of Cancer.

[33]  Jennifer I. Lim,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. , 2003, Ophthalmology.

[34]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[35]  Simon P. Harding,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.

[36]  George A. Williams,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. , 2001, Ophthalmology.

[37]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[38]  U. Schmidt-Erfurth,et al.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. , 2000, Survey of ophthalmology.

[39]  I J Constable,et al.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. , 2000, The American journal of pathology.

[40]  T. Gardner,et al.  Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1 , 1999, The Journal of Biological Chemistry.

[41]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[42]  L. Aiello,et al.  Hypoxic regulation of vascular endothelial growth factor in retinal cells. , 1995, Archives of ophthalmology.